

South East London Area Prescribing Committee
Prescribing Recommendations for Adhesive Removers and Wipes in Stoma Care
Position Statement

| | | | | |
|----------------------------|---|-------------|------------------|-------------|
| Reference: | PS-019 | | | |
| Intervention: | Prescribing Recommendations for Adhesive Removers and Wipes in Stoma Care NOTE: The guidance in this position statement is based on recommendations from the NHS London Procurement Partnership, Medicines Optimisation and Pharmacy Procurement (MOPP) Workstream. | | | |
| Date of Decision: | July 2019 | | | |
| Date of Issue: | July 2019 | | | |
| Recommendation: | Green – Restricted formulary recommended for prescribing in South East London <ul style="list-style-type: none"> Adhesive remover sprays or wipes should be initiated by a stoma care nurse and prescribed in the recommended quantities as per NHS LPP prescribing guidelines and used in collaboration with local guidelines Both sprays and wipes should not be issued except in short-term circumstances. Patients established on a non-approved product should be reviewed with a view to having these stopped and switched to the recommended formulary products. New patients should ideally be initiated on the recommended formulary products unless there are extenuating circumstances e.g. intolerance to formulary products Non formulary adhesive wipes and sprays should not be prescribed on FP10 if no extenuating circumstances are identifiable or informed by the stoma nurses following their review Counsel patients to help them understand that these products for their stoma care are clinically proven to offer value for money and where relevant, changing to them will have no adverse impact on quality of patient care. If patients/GPs want to discuss alternative options they should be encouraged to discuss it with their stoma nurse. | | | |
| Formulary products: | <u>Formulary for approved adhesive remover sprays</u> | | | |
| | <i>1st choice: Aerosol adhesive remover sprays</i> | | | |
| | Product | Code | Fragrance | Size |
| | Medi Lifteez | 60833 | No | 50ml |
| | StoCare | STC100 | No | 50ml |
| | Lift Plus 360 | 5506 | No | 50ml |
| | Lift Plus 360 Citrus | 5507 | Yes | 50ml |
| | <i>2nd choice: Aerosol adhesive remover sprays</i> | | | |
| | Product | Code | Fragrance | Size |
| | EasiSpray Adhesive Remover | 083-01 | No | 50ml |
| | OstoPEEL No Sting Medical Adhesive Remover | OPN50 | No | 50ml |
| | OstoPEEL No Sting Medical Adhesive Remover(apple) | OPA50 | Yes | 50ml |
| | OstoPEEL No Sting Medical Adhesive Remover (Blackberry) | OPB50 | Yes | 50ml |
| | OstoPEEL No Sting Medical Adhesive Remover (Mint) | OPM50 | Yes | 50ml |
| | Salts Adhesive Remover | WAP | Yes | 50ml |
| | Offmate Stoma Adhesive Remover | OM50 | No | 50ml |
| | Elite Sting-Free Silicone Remover | TR201 | No | 50ml |
| | Pelican Platinum Adhesive Remover Vit E | 130400E | No | 50ml |

| | | | | |
|--|---|--|--|--|
| Formulary products continued: | <u>Formulary for approved adhesive remover wipes</u> <i>Preferred choice:</i> Adhesive remover wipes | | | |
| Further Information: | <ul style="list-style-type: none"> • Aerosol sprays offer better value for money than wipes as they are more effective • Silicone based, alcohol free products are preferred as they do not compromise skin integrity or new appliance adhesion • Variations to routine prescriptions requests are likely to occur when a patient's medical condition deteriorates or lifestyle changes • Any red flag concerns must be raised with a stoma care nurse before a prescription is issued • Patients should be advised on the correct use of adhesive remover sprays to minimise waste and maximize savings • Patients on an adhesive remover product should be reviewed annually by a stoma care nurse to prevent inappropriate prescribing or product use • For further information please refer to: http://www.lpp.nhs.uk/media/168072/v2-formulary-for-prescribing-adhesive-removers-in-stoma-care.pdf | | | |
| Cost Impact for agreed patient group: | Across six CCGs in South East London, if there was a switch to lowest acquisition formulary spray including switching non-sting cleansing wipes to sprays, the potential savings opportunity is £99,141 <i>(based on 100% switch)</i> | | | |
| Usage Monitoring & Impact Assessment: | <p>Acute Trusts</p> <ul style="list-style-type: none"> • Stoma products are not listed on the formulary nor stocked by pharmacy. These are provided as free samples by manufacturer and given to patients and subsequently requested on FP10 when patient care is transferred to primary care via a Dispensing Appliance Contractors. • Trusts to monitor requests for these products <p>CCGs</p> <ul style="list-style-type: none"> • Monitor impact 2 data • Review annual review reports by Stoma Nurses which will contain details of appliance review and in particular if inappropriate request to prescribe these products are made in primary care. | | | |
| Evidence reviewed: | <ol style="list-style-type: none"> 1. Burch J. (2012) spoilt for choice: stoma accessories and appliances. Nursing and Residential Care 17(2): 68-70 2. Denver J. (2011) Reducing pain during removal of adhesive and adherent products. British Journal of Nursing 20(15):S28-S35 3. Hopkins G. (2015) Stoma care: changing and removing ostomy pouches. Gastrointestinal Nursing 13 (7): 20-22 4. McNichol L., Lund C., Rosen T., & Gray M. (2013) Medical Adhesives and Patient Safety: State of the Science: Consensus statements for the assessment, prevention, and treatment of adhesive-related skin injuries. Journal of Wound Ostomy Continence Nurse 40(4): 365-80 5. Rudoni C. (2008) A service evaluation of the use of silicone-based adhesive removers. British Journal of Nursing 17(2): S4-S9 6. Recommendations from the NHS London Procurement Partnership, Medicines Optimisation and Pharmacy Procurement, Stoma and Continence Task and Finish Group. http://www.lpp.nhs.uk/ | | | |

NOTES:

- a) Area Prescribing Committee recommendations, position statements and minutes are available publicly via the [APC website](#).
- b) This Area Prescribing Committee position statement has been made on the cost effectiveness, patient outcome and safety data available at the time. The position statement will be subject to review if new data becomes available, costs are higher than expected or new NICE guidelines or technology appraisals are issued
- c) **Not to be used for commercial or marketing purposes. Strictly for use within the NHS.**